公开(公告)号：EP2475366A1

公开(公告)日：2012-07-18

申请号：EP10747893.5

申请日：2010-09-03

申请人： Bayer Pharma Aktiengesellschaft

发明人： CLEVE, Arwed ,  LÜCKING, Ulrich ,  BÄURLE, Stefan ,  FRITSCH, Martin ,  SCHRÖDER, Jens ,  IGL, Bernd-Wolfgang

IPC分类号： A61K31/4439 ,  A61P35/00 ,  A61K31/275

CPC分类号： A61K31/275 ,  A61K31/4439

摘要： The invention refers to the use of androgen receptor antagonists for the treatment and/or prevention of fibroids, also known as uterine leiomyoma, leiomyomata. Particularly, the invention refers to the use of an androgen receptor antagonist being any one of the compounds according to the following list: cyproterone acetate, oxendolone, chlormadinone acetate, spironolactone, osaterone acetate, dienogest, flutamide, hydroxyflutamide, nilutamide, bicalutamide, RU 58841, LGD-2226, MDV3100, BMS-641988, BMS-779333, or 4-(3-{[6-(2-hydroxy-2-methylpropoxy)pyridin-3-yl]methyl}-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl)-2-(trifluoromethyl)benzonitrile (thioxoimidazolidine derivative) for the treatment of fibroids.